NEW YORK, Nov. 7 – GeneProt said Wednesday it had agreed to purchase seven Bruker Daltonics UltraFlex Maldi-TOF/TOF (time of flight/time of flight) mass spectrometers, adding to its already large arsenal of Bruker machinery.
GeneProt, said that six of the new machines would be housed in its headquarters in North Brunswich, NJ. That facility is scheduled to be fully outfitted in the second quarter of next year. The seventh machine has been designated for its European proteomics center in Geneva.
Earlier this year, GeneProt opened the Geneva facility, which already operates 51 Bruker Daltonics mass spectrometers. The machines are used to identify the amino acid sequence of proteins isolated from clinical samples. The company is currently working with Novartis to perform proteomics studies on Novartis’ clinical samples.
The new Maldi-TOF/TOF machines are designed to increase the throughput, sensitivity, and specificity of proteomic studies.
"We are moving very rapidly to utilize cutting-edge TOF/TOF technology in our proteomic drug discovery programs in the near future," Cedric Loiret-Bernal, GeneProt's CEO, said in a statement. "Our scientific experts have carefully analyzed and tested the available MALDI-TOF/TOF systems, and we have come to the conclusion that the UltraFlex TOF/TOF excels in its performance.”
The UltraFlex TOF/TOF, which was launched in July, can generate MS/MS characterization of five to 10 tryptic peptides in less than three minutes using just a few femtomoles of a protein digest, Buker of Billerica, Mass., said. Such an outcome can take more than 30 minutes using LC/MS/MS, said the company.
Financial details of the deal were not disclosed.